Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00003185 · ClinicalTrials.gov registry record · Phase 2
Biological Therapy in Treating Patients With Glioblastoma Multiforme
A Phase 2 study, sponsored by The Cleveland Clinic.
- Completed
- Registry status
- Phase 2
- Development phase
- 40
- Enrollment target
NCT00003185 is a Phase 2 study that has completed, run by The Cleveland Clinic. The registered enrollment target is 40 participants.
The verdict
NCT00003185, a Phase 2 study, has completed, sponsored by The Cleveland Clinic.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 40 participants
- Enrollment target
Study Summary
RATIONALE: Biological therapies use different ways to stimulate the immune system and stop cancer cells from growing. PURPOSE: Phase II trial to study the effectiveness of biological therapy in treating patients with glioblastoma multiforme.
Interventions
- DRUG cyclophosphamide
- PROCEDURE conventional surgery
- BIOLOGICAL sargramostim
- BIOLOGICAL autologous tumor cell vaccine
- BIOLOGICAL tumor-draining lymph node lymphocyte therapy
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 40 participants |
| Start Date | 1997-08 |
| Est. Completion | 1998-07 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00003185
The ClinicalTrials.gov registry entry for NCT00003185 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 40 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is The Cleveland Clinic, which has 688 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which cyclophosphamide is the first listed.
NCT00003185 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00003185 about?
NCT00003185 is a clinical study titled "Biological Therapy in Treating Patients With Glioblastoma Multiforme". RATIONALE: Biological therapies use different ways to stimulate the immune system and stop cancer cells from growing. PURPOSE: Phase II trial to study the effectiveness of biological therapy in treating patients with glioblastoma multiforme.
What is the current status of trial NCT00003185?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 40 participants. The study started on 1997-08. Estimated completion is 1998-07.
What interventions are being tested in trial NCT00003185?
The interventions under investigation include: cyclophosphamide (DRUG), conventional surgery (PROCEDURE), sargramostim (BIOLOGICAL), autologous tumor cell vaccine (BIOLOGICAL), tumor-draining lymph node lymphocyte therapy (BIOLOGICAL).
Who is sponsoring clinical trial NCT00003185?
This trial is sponsored by The Cleveland Clinic, which has 688 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.